Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Healthcare Triangle ( (HCTI) ) has provided an update.
On February 2, 2026, Healthcare Triangle, Inc. held a virtual Special Stockholders Meeting with approximately 66.35% of its outstanding voting shares represented, satisfying quorum requirements under Delaware law and the company’s bylaws. At the meeting, stockholders approved an amendment to the company’s Certificate of Incorporation authorizing a reverse stock split of its common shares at a ratio between 1-for-2 and 1-for-100 to be set by the board, and also approved the option to adjourn the meeting if additional proxy solicitations were needed for that proposal, moves that provide the company with flexibility to manage its capital structure and share price dynamics.
The most recent analyst rating on (HCTI) stock is a Hold with a $0.24 price target. To see the full list of analyst forecasts on Healthcare Triangle stock, see the HCTI Stock Forecast page.
Spark’s Take on HCTI Stock
According to Spark, TipRanks’ AI Analyst, HCTI is a Neutral.
The score is weighed down primarily by weak financial performance—deep ongoing losses, margin compression, and heavy negative free cash flow—alongside a strongly bearish price trend below all major moving averages. Corporate actions provide strategic upside via the AI acquisition, but recent convertible/ATM financing introduces dilution risk, and valuation signals are not supportive due to negative earnings.
To see Spark’s full report on HCTI stock, click here.
More about Healthcare Triangle
Healthcare Triangle, Inc. is a Delaware-incorporated company operating in the healthcare sector, though the specific products, services, and market focus were not detailed in the release.
Average Trading Volume: 8,387,200
Technical Sentiment Signal: Sell
Current Market Cap: $2.5M
Learn more about HCTI stock on TipRanks’ Stock Analysis page.

